Haplotype Analysis of PPARγ Gene Polymorphisms and the Lipoprotein (a) Level

Overview

Journal Iran J Public Health

Date 2018 Sep 6

PMID 30181995

Citations 1

Authors

Chao Shen

Wei Fan

Hui-Jian Xie

Ming Wu

Zheng-Yuan Zhou

Zhi-Rong Guo

Chen Dong

Affiliations

Soon will be listed here.

Abstract

Background: Lipoprotein (a) [Lp(a)], as an independent risk factor for cardiovascular disease, is more likely to be genetically determined according to the increasing evidence of epidemiologic and clinical studies in recent years. Peroxisome proliferator-activated receptor (PPAR) γ, the ligand-activated transcription factors, was considered as an indispensable role in the process of lipid metabolism. This study was designed to explore the associations of three single-nucleotide polymorphisms (SNPs) and the haplotypes of the peroxisome proliferator-activated receptor (PPAR)γ gene with the level of Lp(a).

Methods: Participants were recruited under the framework of the PMMJS (The Prevention of Metabolic Syndrome (MS) and Multi-metabolic Disorders in Jiangsu Province of China Study) from Apr 1999 to Jun 2004. Overall, 644 subjects were randomly selected and 3 SNPs of PPARγ gene (rs10865710, rs1805192, rs4684847) were genotyped.

Results: After adjusting for age, sex, cigarette smoking, alcohol drinking, waist circumference and body mass index, rs4684847 was significantly associated with Lp (a). The presence of the rs4684847 T allele (CT+TT) have a lower level of Lp (a) than the allele (CC) in the dominant model, mean difference was -27.30 (95% : -52.88∼-1.73) mg/L, <0.05. G-P-T and G-A-T haplotype were associated with lower levels of Lp (a) (=0.0041 and <0.0001), mean difference was 49.79 (95% -97.52∼-2.06) mg/L and 17.75 (95% : -25.75∼-9.75) mg/L.

Conclusion: PPAR gamma polymorphisms (rs10865710, rs1805192, rs4684847) and haplotypes may be the genetic risk factors for Lp (a) level.

Citing Articles

LPL, FNDC5 and PPARγ gene polymorphisms related to body composition parameters and lipid metabolic profile in adolescents from Southern Italy.

Perrone B, Ruffo P, Zelasco S, Giordano C, Morelli C, Barone I J Transl Med. 2022; 20(1):107.

PMID: 35241092 PMC: 8895817. DOI: 10.1186/s12967-022-03314-w.

References

Xie H, Hai B, Guo Z, Zhou Z, Liu M, Wu M . [Association between polymorphisms, haplotypes of peroxisome proliferators activated receptor a gene and the level of lipoprotein (a)]. Zhonghua Liu Xing Bing Xue Za Zhi. 2014; 35(7):787-91. View

Sharrett A, Ballantyne C, Coady S, Heiss G, Sorlie P, Catellier D . Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001; 104(10):1108-13. DOI: 10.1161/hc3501.095214. View

Yu L, Zhou Z, Guo Z, Wu M, Gu S . [Roles of peroxisome proliferator-activated receptors polymorphisms, haplotypes, levels on C-reactive protein and their interactions with abnormal body weight]. Zhonghua Liu Xing Bing Xue Za Zhi. 2014; 34(10):1023-9. View

Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M . Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008; 168(6):598-608. DOI: 10.1001/archinte.168.6.598. View

Frederiksen L, Brodbaek K, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S . Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab. 2002; 87(8):3989-92. DOI: 10.1210/jcem.87.8.8732. View

Cain W, Millar J, Himebauch A, Tietge U, Maugeais C, Usher D . Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res. 2005; 46(12):2681-91. DOI: 10.1194/jlr.M500249-JLR200. View

Azhar S . Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 2010; 6(5):657-91. PMC: 3246744. DOI: 10.2217/fca.10.86. View

Hu X, Guo Z, Zhou H, Shi Z, Wu M, Zhang J . [Study on the prevalence of metabolic syndrome among 35-74 year-olds in Jiangsu province]. Zhonghua Liu Xing Bing Xue Za Zhi. 2007; 27(9):751-6. View

Memon R, Tecott L, Nonogaki K, Beigneux A, MOSER A, Grunfeld C . Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in.... Endocrinology. 2000; 141(11):4021-31. DOI: 10.1210/endo.141.11.7771. View

10.

Erqou S, Kaptoge S, Perry P, Di Angelantonio E, Thompson A, White I . Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302(4):412-23. PMC: 3272390. DOI: 10.1001/jama.2009.1063. View

11.

Kamstrup P, Tybjaerg-Hansen A, Nordestgaard B . Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol. 2012; 32(7):1732-41. DOI: 10.1161/ATVBAHA.112.248765. View

12.

Werner C, Schirmer S, Gensch C, Pavlickova V, Poss J, Wright M . The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis. Br J Pharmacol. 2014; 171(10):2685-703. PMC: 4009009. DOI: 10.1111/bph.12608. View

13.

Berger J, Leibowitz M, Doebber T, Elbrecht A, Zhang B, Zhou G . Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999; 274(10):6718-25. DOI: 10.1074/jbc.274.10.6718. View

14.

Zhou H, Guo Z, Yu L, Hu X, Xu B, Liu H . Evidence on the applicability of the ATPIII, IDF and CDS metabolic syndrome diagnostic criteria to identify CVD and T2DM in the Chinese population from a 6.3-year cohort study in mid-eastern China. Diabetes Res Clin Pract. 2010; 90(3):319-25. DOI: 10.1016/j.diabres.2010.09.001. View

15.

Gallicchio L, Kalesan B, Huang H, Strickland P, Hoffman S, Helzlsouer K . Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland. PPAR Res. 2008; 2008:276581. PMC: 2233806. DOI: 10.1155/2008/276581. View

16.

Kamstrup P, Tybjaerg-Hansen A, Steffensen R, Nordestgaard B . Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009; 301(22):2331-9. DOI: 10.1001/jama.2009.801. View

17.

Palmer L, Cardon L . Shaking the tree: mapping complex disease genes with linkage disequilibrium. Lancet. 2005; 366(9492):1223-34. DOI: 10.1016/S0140-6736(05)67485-5. View

18.

Lanktree M, Anand S, Yusuf S, Hegele R . Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet. 2010; 3(1):39-46. DOI: 10.1161/CIRCGENETICS.109.907642. View

19.

Stumvoll M, Haring H . The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes. 2002; 51(8):2341-7. DOI: 10.2337/diabetes.51.8.2341. View

20.

Xie H, Hai B, Wu M, Chen Q, Liu M, Dong C . Analysis on the association between PPARα/γ polymorphisms and lipoprotein(a) in a Chinese Han population. Mol Genet Genomics. 2014; 289(5):981-7. DOI: 10.1007/s00438-014-0866-9. View